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Abstract
Objectives—To estimate the cost-effectiveness of Haemophilus influenzae type b (Hib) 
conjugate vaccine in low-and middle-income countries and identify the model variables, which are 
most important for the result.
Study design—A static decision tree model was developed to predict incremental costs and 
health impacts. Estimates were generated for 4 country groups: countries eligible for funding by 
the GAVI Alliance in Africa and Asia, lower middle-income countries, and upper middle-income 
countries. Values, including disease incidence, case fatality rates, and treatment costs, were based 
on international country estimates and the scientific literature.
Results—From the societal perspective, it is estimated that the probability of Hib conjugate 
vaccine cost saving is 34%–53% in Global Alliance for Vaccines and Immunization eligible 
African and Asian countries, respectively. In middle-income countries, costs per discounted 
disability adjusted life year averted are between US$37 and US$733. Variation in vaccine prices 
and risks of meningitis sequelae and mortality explain most of the difference in results. For all 
country groups, disease incidence cause the largest part of the uncertainty in the result.
Conclusions—Hib conjugate vaccine is cost saving or highly cost-effective in low- and middle-
income settings. This conclusion is especially influenced by the recent decline in Hib conjugate 
vaccine prices and new data revealing the high costs of lost productivity associated with 
meningitis sequelae.
Prior to the introduction of vaccines, Haemophilus influenzae type b (Hib) was the most 
common cause of bacterial meningitis and an important cause of pneumonia in children < 5 
years of age. Hib conjugate vaccines became available during the early 1990s, and high-
income countries quickly introduced the vaccine into routine vaccination programs, resulting 
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in a near disappearance of Hib disease.1 However, relatively high vaccine prices and 
uncertainties about Hib disease burden led to slow uptake in low- and middle-income 
countries. Even though the GAVI Alliance began to offer Hib conjugate vaccine to the 
poorest countries of the world in 2001, it took almost a decade until the majority of these 
had introduced the vaccine.2 Similar late introductions were seen in middle-income 
countries. Although 181 of the world’s 196 countries (92%) had adopted the vaccine by 
2012, 52% of these had only done so during the past 8 years.3
To better understand the relative contribution of costs, health systems aspects, and disease 
variables for assessment of the value of vaccines, this study was conducted to determine and 
compare the cost-effectiveness of Hib conjugate vaccine between countries in various 
income and epidemiologic categories.
Methods
A deterministic, aggregate-level, static decision tree model was developed. The model 
framework is seen in Figure 1. Hib disease was divided into 3 different groups: (1) 
meningitis; (2) pneumonia; and (3) less common non-pneumonia-non-meningitis (NPNM), 
following methods used in the Hib Global Burden of Disease (GBD) Study.4 Projected 
numbers of person-years lived between 1 and 59 months were multiplied by age-specific 
disease incidence rates to estimate Hib cases in each cohort. The time horizon was until 
everyone in the cohort had died.
An all-cause pneumonia incidence rate was used to calculate total pneumonia cases, and a 
proportion of these were assumed to be attributable to Hib. Cases of Hib meningitis and Hib 
NPNM were calculated directly from etiology-specific incidence rates. Numbers of deaths 
were estimated from case fatality ratios (CFRs). A risk of sequelae was applied to all 
survivors of Hib meningitis and classified according to type of complication. A proportion 
of cases were assumed to seek health care and treatment costs varied according to outpatient 
visits and hospital admissions. The analysis was undertaken from both a government health 
sector and a societal perspective; the difference being that household out-of-pocket treatment 
costs and meningitis sequelae productivity costs were only included in the societal 
perspective.
The impact of Hib conjugate vaccine was estimated as the difference between scenarios with 
and without vaccination. In the Hib conjugate vaccine scenario, cases were reduced by age-
specific vaccination coverage rates and dose-specific vaccine efficacy. Incremental cost-
effectiveness ratios (ICERs) were calculated by subtracting annual treatment costs from 
annual vaccine delivery costs and dividing by incremental health effects, expressed as 
disability adjusted life years (DALYs) averted. Future costs and health effects were 
discounted by 3% per year.5
Monte Carlo Simulation
Most parameter values in decision-analytic modeling are surrounded by uncertainty.6 In the 
present study, this is important because a number of international sources and global 
assumptions were used, which have not been reviewed at country level. Thus, the aim was 
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not to generate results for a single country, but to determine a plausible range of cost-
effectiveness for a given country income and epidemiologic group. Uncertain parameter 
values were assigned an uncertainty range and a statistical distribution, and 1000 random 
sample Monte Carlo simulations were run using Crystal Ball software (Oracle, Redwood 
Shores, California). This generated 95% CIs around the ICERs. The importance of 
individual parameters to uncertainty in the result was assessed by ANCOVA, which 
summarizes the proportion of the variance explained by variation in different input 
variables.6 The simulation data were analyzed in Stata v. 11.0 (StataCorp, College Station, 
Texas). All variables are seen in Table I. The statistical distributions fitted to the variables 
are included in the Appendix (available at www.jpeds.com).
Study Populations
The model was run for cohorts of 1 million children in 4 different settings: (1) GAVI-eligible 
African countries; (2) GAVI-eligible Asian countries; (3) lower middle-income countries; 
and (4) upper middle-income countries. In 2012, GAVI offered support to countries with 
2011 Gross National Income (GNI) per capita below US$1520.7 Lower middle-income 
countries were classified as those with per capita GNI between the GAVI threshold and US
$4035, and upper middle-income countries were those with GNI per capita between US
$4036 and US$12 475.8 The countries included in the 4 groups are listed in the Appendix. 
Several model input parameters were estimated as averages across the country groups. Since 
the results of the analysis is targeted country Governments, these averages were not 
weighted according to population size.
Hib Disease Incidence Rates
Country-specific studies have shown great variation in Hib disease incidence rates, and this 
has been the subject of much research and some controversy.9 One of the most debated 
topics is the disease incidence in Asia where some studies have shown rates one-tenth of 
those observed in North America and Europe.10,11 There is still not enough knowledge to 
conclude whether these results reflect a true low disease burden or whether they are due to 
problems in detection, such as widespread use of antibiotics before hospitalization and/or 
suboptimal microbiologic capacity for identifying Hib in clinical specimens.12
Hib meningitis incidence rates for the 4 groups were calculated as averages of the Hib GBD 
study country-specific estimates for the year 2000. The GBD study authors conducted a 
systematic literature review and extrapolated published estimates to countries without 
data.4,13 The uncertainty range was assumed as the lowest and highest country-specific 
values of the respective group. NPNM incidence was estimated as a proportion of the 
meningitis incidence rates, as explained in the Appendix.
The most uncertain disease burden estimate is for Hib pneumonia. In 2008, pneumonia 
deaths in children aged 1–59 months caused approximately 14% of global deaths in children 
<5 years of age, and Hib conjugate vaccines are seen as an important tool to reduce this 
mortality.14 However, the true incidence of Hib pneumonia is largely unknown because the 
signs and symptoms attributable to Hib cannot be differentiated from cases caused by other 
microorganisms.15 The incidence of clinical pneumonia for the 4 country groups were taken 
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from recently completed estimates for the 2010 GBD study.16 Details on these are given in 
the Appendix. Hib conjugate vaccine trials in Indonesia and Gambia have demonstrated 
efficacy against all cause clinical pneumonia with a pooled estimate of 4% (95% CI 1%–
7%) and no heterogeneity between the 2 studies,17–19 and this was assumed as the vaccine 
preventable proportion.
Case Fatality Rates and Risk of Meningitis Sequelae
The risk of mortality from Hib disease increases substantially if access to antibiotics and 
appropriate treatment are not available. Without access to health care, case fatality rates were 
assumed to be 100% for meningitis, 50% for NPNM, and 24% for pneumonia.20,21 Hospital 
case fatality rates were based on studies from the respective regions and a global review.9
The risk of meningitis sequelae increases with delay in treatment as untreated patients are 
likely to experience coma, seizures, and prolonged fever.22 Estimates were taken from a 
meta-analysis of the risk of sequelae according to pathogen, region, and country income 
group.23
DALYs
DALYs were calculated as the sum of 3 components: years of life lost due to premature 
mortality, years of life with disability from acute disease, and years of life with disability 
due to meningitis sequelae. Average life expectancies across the 4 country groups were used 
for the years of life lost estimates. Disability weights were 0.279 and 0.616 for pneumonia 
and meningitis, respectively.24 In the original GBD Study, there were no disability weights 
for any of the NPNM diseases, probably because these are all relatively rare syndromes. In 
such instances, it is common practice to use a disability weight for a comparable disease. For 
middle-income countries, the meningitis disability weight was used because epiglottitis has 
comparable severity to meningitis. For the low-income groups, the pneumonia disability 
weight was used, as there is currently no evidence of epiglottitis in these countries and the 
remaining NPNM diseases have more comparable severity with pneumonia than to 
meningitis (Appendix).
To estimate DALYs attributable to meningitis sequelae, the proportional distributions of 
sequelae complications were determined from the literature review by Edmond et al23 and 
appropriate disability weights were assigned. The weighted average disability weight for 
meningitis sequelae was 0.340 (Appendix).
Access to Health Care
Assumptions about access to care were expressed in terms of number of outpatient visits and 
hospital admissions per case. According to World Health Organization treatment 
recommendations, all Hib disease, except nonsevere pneumonia, requires hospitalization.25 
Hence, if all children had access to appropriate health care, each case of meningitis, NPNM, 
and severe pneumonia would lead to at least 1 hospitalization and most likely also at least 1 
outpatient visit, as hospitalizations are generally referred during an outpatient consultation. 
The number of outpatient visits per case would exceed one in places with high access to care 
as clinical follow-up is commonly recommended after hospital discharge, especially for 
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meningitis. If access to health care is limited, the number would be less than 1. For those 
with access to care, it was assumed that: (1) each meningitis episode would lead to 1 
hospital admission and 3 outpatient visits; (2) each severe pneumonia or NPNM episode 
would lead to 1 hospital admission and 1 outpatient visit; and (3) each nonsevere pneumonia 
episode would lead to 1 outpatient visit only. Based on evidence from the Indonesia Hib 
conjugate vaccine trial, 17% of clinical cases of Hib pneumonia were presumed severe.18 
Assumptions about access to care were based on the percentage of children with acute 
respiratory symptoms taken to a health facility reported in Demographic and Health surveys 
from the respective regions since 2000.26
Treatment Costs
Hospital treatment—Data were extracted from country-specific studies reporting on the 
costs of pneumonia and meningitis treatment (Appendix). Nine studies with pneumonia data 
and 21 studies with meningitis data were identified. For both syndromes, there were strong 
correlations between mean costs per case and GNI per capita and the following regressions 
were generated: (1) costs of meningitis treatment in tertiary hospital = US$774 + 0.2645 
(GNI); and (2) costs of pneumonia treatment in tertiary hospital = US$54 + 0.1255 (GNI). 
CIs around the regression coefficients were used for the uncertainty ranges.
Treatment costs of NPNM were assumed similar to pneumonia. Based on evidence from 3 
studies that provided estimates from different levels of facilities, mean treatment costs in 
secondary facilities were 65%, 71%, and 27% less than in tertiary facilities, for low-income 
African countries, low-income Asian, and middle-income countries, respectively 
(Appendix). In upper middle-income countries, it was assumed that 30% of cases of 
meningitis and severe pneumonia were admitted to tertiary hospitals and the remaining to 
secondary hospitals. For the remaining 3 regions, 20% of cases were supposed admitted to 
tertiary hospitals and 80% to secondary.
The proportion of treatment costs paid by household as out-of-pocket payments was 
calculated as averages of country-specific data from National Health Accounts.27 These 
were 45% in low-income African countries, 51% in low-income Asian countries, 37% in 
lower middle-income countries, and 31% for upper middle-income countries.
Outpatient Treatment—Country-specific estimates from World Health Organization 
Choosing Interventions that are Cost Effective on the costs per outpatient visit were 
averaged across the 4 country groups.28 These estimates; however, do not include the costs 
of drugs and diagnostics. In a study from Fiji, mean costs of drugs and medical supplies for 
pneumonia outpatient treatment of 387 children <5 years of age were estimated as US$1.28 
per case.29 This amount was added to the visits costs in all 4 country groups. For the 
uncertainty intervals, the mean estimates were varied by 25% in each direction.
Meningitis Sequelae—The costs of meningitis sequelae have rarely been included in Hib 
conjugate vaccine economic evaluations from low- and middle-income countries.30 This is 
in contrast to high-income country studies where sequelae costs have been one of the most 
important determinants of cost-effectiveness and a key supporting argument for the 
vaccine.31,32 In these countries, cost estimates were based on data from education agencies, 
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disability services, and medical insurance companies. These assumptions; however, can not 
easily be made for low- and middle-income countries with limited access to health care and 
hardly any disability rehabilitation services. In a recent study from Senegal, data were 
collected from 49 families with children suffering from meningitis sequelae. Mean 
nondiscounted lifetime sequelae costs were estimated at US$53 165 (95% CI US$68-$148 
067) per child, with treatment costs comprising 1%, childcare costs 9%, and productivity 
costs of caregivers 90%.33 The costs of meningitis sequelae were approximately 26 times 
higher than the mean costs of treatment of the acute meningitis episode, and this result was 
used in the present analysis for the 4 country groups. As the costs of sequelae are primarily 
borne by households in low- and middle-income countries, these costs were only included in 
the societal perspective.
Costs of Hib Conjugate Vaccine Delivery
Incremental vaccine delivery costs were estimated as the difference between a routine 
vaccination schedule with and without Hib conjugate vaccine. Use of Hib combination 
vaccines was assumed. For GAVI-eligible countries the difference in 2011 United Nations 
Children’s Fund prices of the 10 dose diphtheria-tetanus-pertussis (DTP)-hepatitis B-Hib 
conjugate vaccine and the 10 dose DTP-hepatitis B vaccine amounted to US$1.13 per dose 
(US$1.75-US$0.62).34 For upper middle-income countries, Belarus prices of US$5.30 per 
dose of DTP-Hib conjugate vaccine and US$0.15 per dose of DTP were used.21 Hence, the 
incremental costs per dose were US$4.95. In the lower middle-income group several 
graduating GAVI countries are included, and the price that these countries will obtain after 
GAVI support ends is still uncertain.35 An incremental price of US$3 per Hib conjugate 
vaccine dose was assumed. A 3-dose schedule was used in low- and lower middle-income 
countries and a 4-dose schedule in upper middle-income countries, reflecting common 
practices.36 It was assumed that upper middle-income countries used single dose vials and 
the remaining countries 10-dose vials, with vaccine wastage of 25% (range 20%–30%) for 
10 dose and 5% (range 2%–7%) for single dose vials.7
Results
Health Impact, Net Costs, and Costs per Discounted DALY Averted
Base case health impacts and incremental costs from a societal perspective are summarized 
in Table II. Per 1 million birth cohort, the vaccine is predicted to avert 4589 deaths in GAVI-
eligible African countries, 3505 in GAVI-eligible Asian countries, 4048 in lower middle-
income countries, and 1446 in upper middle-income countries. Pneumonia comprises 
between 82% and 87% of all premature deaths averted. The lower middle-income group is 
the most heterogeneous as health indicators vary considerably between the countries; the 
mortality rate of children <5 years of age per 100 000 ranges from 15 in Ukraine to 128 in 
Congo Brazzaville. This result, therefore, should be considered the most uncertain and the 
heterogeneity explains the relatively high proportion of mortality averted in children <5 
years of age by Hib conjugate vaccine, which is 10% in the lower middle-income group, but 
only between 4% and 5% in the other 3 groups. The Hib GBD study estimated that Hib 
disease caused 4% of mortality in children <5 years of age in 2000.4 When using an <5 
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years of age mortality of 100 instead of 37 in the lower middle-income group, the vaccine is 
predicted to avert 4% of mortalities in children <5 years of age.
In the base case, Hib conjugate vaccine is cost saving from a societal perspective in GAVI-
eligible African countries, which means that health care costs avoided exceed the costs of 
Hib conjugate vaccine delivery (Table III). Incremental costs also are considerably less in 
GAVI-eligible Asia than in the 2 middle-income country groups. This difference is 
particularly due to the lower vaccine price but also explained by the greater risk of 
meningitis sequelae, which leads to higher averted sequelae costs. From a government 
perspective, incremental costs per discounted DALY averted range from US$35 (95% CI 19, 
57) in GAVI-eligible African countries to US$453 (95% CI 202, 796) in upper middle-
income countries (Table III).
Contribution of Uncertain Model Parameters
The distribution of 1000 Monte Carlo simulations generated from the societal perspective is 
seen in Figure 2. The simulations predict that the probabilities of the vaccine being cost-
saving are 53%, 34%, 0.1%, and 1.6% in GAVI-eligible African, Asian, lower middle-
income, and upper middle-income countries, respectively. A total of 40 variables were 
attached an uncertainty range and a statistical distribution, but only a few influenced 
variability in the ICERs to a substantial extent (Figure 3). From the government perspective, 
pneumonia incidence is the most important variable, contributing to 53% of the variance in 
upper middle-income countries and 78% in GAVI-eligible Asia. However, from a societal 
perspective, the meningitis incidence is the most important because sequelae costs are 
included. This variable is especially important in the GAVI-eligible countries because of the 
higher risk of sequelae in settings with limited access to health care services.
Other variables influencing the result, albeit considerably less than the pneumonia and 
meningitis incidence rates, are Hib conjugate vaccine wastage, CFRs, and vaccine efficacy. 
Vaccine wastage is important because this affects vaccine costs. Because no uncertainty 
range was assumed for vaccine prices, the wastage rates were the only variables that 
influenced vaccine delivery costs. Even with a relatively narrow uncertainty range, this 
variable proved to be more important than many of the others, such as treatment costs and 
health care utilization.
Discussion
This study shows that Hib conjugate vaccine is cost saving in GAVI-eligible Africa and 
highly cost-effective in low- and middle-income settings. These findings are especially 
influenced by the recent decline in Hib conjugate vaccine prices and new data revealing the 
high costs of lost productivity associated with meningitis sequelae.
The cost-effectiveness of Hib conjugate vaccine is more favorable in GAVI-eligible than 
middle-income countries. The most important reason for the difference is the lower vaccine 
price obtained by GAVI compared with when countries procure independently. Another 
critical explanation is that the baseline Hib mortality burden, expressed as case fatality rates, 
is higher, leading to more deaths averted per child vaccinated. However, Hib conjugate 
Griffiths et al. Page 7
J Pediatr. Author manuscript; available in PMC 2018 January 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
vaccine can be considered highly cost-effective in all the analyzed country groups. The 
average GNI per capita of the upper middle-income group is US$7259, which is 10–93 
times more than the societal cost-effectiveness range of US$78–US$733.
The Monte Carlo simulation incorporated parameter uncertainty into the analysis, and it was 
shown that variations in cost-effectiveness are explained by only a few variables. As might 
have been expected, Hib pneumonia and meningitis incidences were the most important 
drivers of the result. Hib pneumonia was important both because this is the most frequent 
type of Hib disease and because of the relatively wide uncertainty range. The burden of 
clinical as well as etiologic-specific pneumonia is intrinsically difficult to determine, and 
this remains the most important ambiguity when making conclusions about the value of Hib 
conjugate vaccine.15,37 Because the reliability of the data for Hib meningitis are 
considerably better than for Hib pneumonia, the uncertainty range is less. However, because 
of the high costs of lost productivity attributable to meningitis sequelae, Hib meningitis 
incidence was the most important determinant of cost-effectiveness from the societal 
perspective. The present study shows the importance of incorporating sequelae costs in low-
income settings. A recent study from Senegal showed that the costs to families of caring for 
a disabled child are substantial.33 When these costs were included, the cost-effectiveness 
range includes negative values, meaning that there is probability of the vaccine being cost 
saving. Similar conclusions were made in high-income country studies twenty years ago.30
There are some important limitations to this analysis. First, this evaluation did not include all 
variables available for use in our model. In particular, herd effects (modeled by increasing 
the direct effect by a simple percentage), clustering of deaths in the unvaccinated group, and 
reductions in the baseline trend of Hib disease mortality in the absence of vaccination. Each 
of these has proven to be influential in simpler univariate analysis. Second, the ranges 
chosen for each variable reflect the extreme range of available country-level estimates in a 
given region/income strata. The variable distributions therefore reflect regional variation, 
which may be wider than the degree of variation expected at country level. Cost-
effectiveness may, thus, appear particularly sensitive to parameters with large variation, 
which may, to some extent, be explained by fairly extreme outliers. Third, this analysis has 
assumed independence between parameters in each “run” of the Monte Carlo simulation (ie, 
that no correlation exists between them). For example, in reality, countries with high 
meningitis CFRs also are likely to have high pneumonia CFRs, but this link is not reflected.
Our analysis is a global economic evaluation of Hib conjugate vaccine. Several country-
specific studies have been published, but only a few of these are from low-and middle-
income countries.30 Our multicountry study provides broad conclusions about the cost-
effectiveness of Hib conjugate vaccine, which is currently valuable. During the first 10 years 
of GAVI support, Hib conjugate vaccine prices remained substantially higher than prices of 
the traditional vaccines, contributing to slow uptake. However, additional vaccine suppliers 
entered the market during 2011, and the price has since decreased. The 10-dose pentavalent 
vaccine from Serum Institute of India (Chennai, India) is procured for approximately 50% 
less than previous price levels.34 Our comparison between GAVI-eligible and middle-
income countries clearly showed the importance of the lower vaccine price for cost-
effectiveness of the vaccine. Middle-income countries have not yet benefited from price 
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decreases, and 17 of these have not yet introduced the vaccine.3 However, our analysis 
showed that Hib conjugate vaccine is highly cost-effective across all current price levels. 
This result is important for countries that are graduating from GAVI support in the near 
future.35
Global economic evaluations of pneumococcal, rotavirus, and human papillomavirus 
vaccines have used comparable methods to the present study and similar conclusions have 
been made for these vaccines.38–42 It is important to note that the unique purpose of these 
global analyses is not to provide accurate cost-effectiveness estimates for a given country, 
but to give an indication of what the plausible range of cost-effectiveness is likely to be for 
countries in a particular region/income strata, and to identify the most important 
determinants of cost-effectiveness for those countries. An alternative approach could have 
been to run the analysis for all countries separately, as in the studies by Kim et al and Goldie 
et al.39,42 However, this level of disaggregation could be misleading because a number of 
country-specific estimates are generated without any primary data collection. If cost-
effectiveness estimates are to have any real influence on decision-making at country-level, 
countries need to have ownership over the data, assumptions, and results of the model. To 
facilitate this, the model used in this study has a user-friendly interface and automated 
features for sensitivity and scenario analysis.43 The model is available for use by Ministries 
of Health who wish to assess the cost-effectiveness of Hib conjugate vaccination and 
populate the model with data that is credible at country level. In addition to Hib conjugate 
vaccine, our model can be used for other vaccines that contribute to prevention of 
pneumonia and meningitis, as it takes into account various factors associated with 
pneumonia assumptions, as well as the costs related to meningitis long-term sequelae.
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Glossary
CFR Case fatality ratio
DALY Disability adjusted life year
DTP Diphtheria-tetanus-pertussis
GBD Global Burden of Disease
GNI Gross National Income
Hib Haemophilus influenzae type b
ICER Incremental cost-effectiveness ratio
NPNM Non-pneumonia-non-meningitis
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Appendix
Country Groups
Countries included in the 4 country groups analyzed are listed in Table I.
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NPNM Disease Incidence Rates
The most common Hib diseases are meningitis and pneumonia. Other severe forms of Hib 
disease are epiglottitis and septicemia. Epiglottitis is a swelling and inflammation of the 
epiglottis and surrounding structures. The disease is considered a medical emergency 
because of the risk of sudden death from acute airway obstruction.1 Septicemia occurs when 
an organism such as Hib enters the blood stream. It may cause no symptoms and resolve 
without treatment, but it also can be a serious, life-threatening infection. If left untreated, 
Hib septicemia develops to meningitis in approximately 25% of cases.1 Rarer forms of 
invasive Hib diseases are cellulitis, osteomyelitis, septic arthritis, and pericarditis, which are 
infections of the skin, bones, joints, and lining of the heart, respectively. However, these are 
predominantly caused by other microbial agents than Hib. Since other Hib infections than 
meningitis and pneumonia are relatively rare, these were grouped into 1 syndrome as NPNM 
Hib disease.
Table I
Country groups
GAVI-eligible Africa GAVI-eligible Asia Lower middle-income Upper middle-income
Benin Afghanistan Albania Algeria
Burkina Faso Bangladesh Armenia* Angola*
Burundi Cambodia Belize Argentina
Cameroon North Korea Bhutan* Azerbaijan*
Central African Rep. India Bolivia* Belarus
Chad Myanmar Cape Verde Bosnia and Herzegovina
Comoros Nepal Congo-Brazzaville* Botswana
Côte d’Ivoire Pakistan Egypt Brazil
Dem Rep of Congo Papua New Guinea El Salvador Bulgaria
Djibouti Solomon Islands Fiji Chile
Ethiopia Timor-Leste Georgia* China
Gambia Uzbekistan Guatemala Colombia
Ghana Guyana Costa Rica
Guinea Honduras* Dominican Republic
Guinea-Bissau Indonesia* Ecuador
Kenya Iraq Gabon
Lesotho Moldova* Grenada
Liberia Mongolia* Iran
Madagascar Morocco Jamaica
Malawi Paraguay Jordan
Mali Philippines Kazakhstan
Mauritania Samoa Latvia
Mozambique Sri Lanka* Lebanon
Niger Swaziland Lithuania
Nigeria Tonga Macedonia
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GAVI-eligible Africa GAVI-eligible Asia Lower middle-income Upper middle-income
Rwanda Ukraine* Malaysia
Sao Tome and Principe Vanuatu Mauritius
Senegal Mexico
Sierra Leone Montenegro
Somalia Namibia
Sudan Panama
Togo Peru
Uganda Romania
Tanzania Russia
Yemen Saint Lucia
Zambia St Vincent
Zimbabwe Serbia
South Africa
Thailand
Tunisia
Turkey
Turkmenistan
Uruguay
Venezuela
*GAVI graduating country.
To determine the disease incidence relationship between Hib meningitis and Hib NPNM, 
surveillance studies reporting on all types of Hib diseases identified for the Hib GBD Study 
were reviewed.2 The 22 ascertained studies are summarized in Table II. Although epiglottitis 
was the most common type of NPNM in the European and Australian studies, this disease 
was not detected in the studies from Bulgaria, The Gambia, India, Israel, South Africa, and 
Thailand. Low rates of epiglottitis also have been observed in indigenous populations in 
developed countries, such as in Australian Aboriginals.3,4 The reason for this geographic- 
and population-specific difference is unclear but may relate to age exposure.5 Epiglottitis is 
most often seen in children >2 years of age, so in places where Hib disease mainly occurs in 
children <2 years, the incidence of epiglottitis is likely to be low.
The estimates from the 2 Gambian studies were used for low-income Africa, the Indian 
study for low-income Asia, the South African study for lower middle-income countries, and 
the mean of the studies from Argentina, Bulgaria, Czech Republic, Guatemala, Jamaica, and 
Thailand were used for upper middle-income countries. The rates between cases of NPNM 
and meningitis were 0.06 in low-income Africa, 0.18 in low-income Asia, 0.12 in lower 
middle-income, and 0.35 in upper middle-income countries. When using these proportions 
in relation to the Hib meningitis disease incidence rates, NPNM incidence per 100 000 
children aged <5 years were 3 (1, 6) in low-income Africa, 6 (1, 13) in low-income Asia, 4 
(1, 13) in lower middle-income countries, and 8 (1, 34) in upper middle-income countries.
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Clinical Pneumonia Incidence Rates
Although a large proportion of cases of pneumonia are relatively mild and can be treated 
without hospitalization, pneumonia also can develop into a severe and critical form. Very 
severe pneumonia is characterized by acute respiratory distress where the child is not able to 
drink, severe pneumonia is distinguished by chest indrawing, and nonsevere pneumonia is 
diagnosed by measuring fast breathing.28 However, estimation of childhood pneumonia 
incidence rates is problematic because there is no single definition that is sensitive, specific, 
and can be widely implemented.29 Second, many common conditions, including malaria, 
bacterial sepsis, and severe anemia, produce a spectrum of clinical symptoms and signs that 
overlaps with pneumonia, and it is difficult to differentiate between these conditions. Third, 
because disease severity varies widely, it is difficult to capture all cases in routine 
surveillance and in population-based studies.
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Table III
2010 GBD incidence estimates for lower respiratory infections*
Region Annual number of cases per 100 000 children aged <5 y
North America, High Income 9555
Latin America, Southern 10 750
Europe, Western 8500
Australasia 5995
Asia Pacific, High Income 5580
Europe, Eastern 10 245
Europe, Central 9755
Asia, Central 6440
Sub-Saharan Africa, West 19 675
Sub-Saharan Africa, Southern 15 855
Sub-Saharan Africa, East 26 125
Sub-Saharan Africa, Central 26 975
North Africa/Middle East 21 035
Asia, South 31 695
Asia, Southeast 15 865
Asia, East 12 215
Oceania 20 705
Latin America, Tropical 21 880
Latin America, Central 30 980
Latin America, Andean 26 585
Caribbean 33 310
Global 21 590
Source: Lozano et al.32
*
Mean value between male and female estimates.
Global childhood pneumonia disease burden estimates were first prepared by Rudan et al in 
2004 and updated in 2008.30,31 New estimates have recently been completed for the 2010 
GBD study. The GBD authors used 3 data sources for estimating the incidence of respiratory 
infections32: (1) a comprehensive literature review conducted by an expert group; (2) 
individual-level data from Demographic and Health Surveys and World Health Surveys; and 
(3) hospital discharge data from the US, Brazil, and 20 European countries.
Table IV
Annual clinical pneumonia incidence per 100 000 children aged <5 years used for the four 
country groups
Country group GBD regional estimates used Mean Low High
Low-income Africa West Africa 24 258 19 675 26 975
East Africa
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Country group GBD regional estimates used Mean Low High
Central Africa
Low-income Asia South East Asia 23 780 15 865 31 695
South Asia
Lower middle-income Central Latin America 21 300 12 215 30 980
East Asia
Oceania
Upper middle-income Europe Eastern 14 733 9755 21 880
Europe Central
Latin America Southern
North Africa
Tropical Latin America
Upper respiratory infections were defined as children in surveys with cough and fever but no 
difficulty breathing and lower respiratory infections as children with cough, fever, and 
difficulty breathing. The GBD lower respiratory incidence estimates are summarized in 
Table III. There is marked variation across regions, ranging from 5580 in Asia Pacific to 33 
310 per 100 000 children aged <5 years in the Caribbean. Estimates for the 4 country groups 
were calculated as averages of the regional GBD numbers as seen in Table IV.
Meningitis Sequelae DALY Disability Weight
In a systematic literature review by Edmond et al, sequelae types were divided into minor 
and major forms and a multiple impairment category was developed for children suffering 
from more than 1 disability type.33 The case definitions are summarized in Table V. Four of 
the major sequelae case definitions were taken directly from the 1996 GBD study: cognitive 
deficit, seizures, hearing loss, and motor deficit. However, these were the only types of 
meningitis sequelae included in the original GBD study, with the associated disability 
weights found under the “meningococcemia without meningitis” category in the disability 
weight list as “mental retardation,” “seizure disorder,” “deafness,” and “motor deficit.”34 
Since there were no associated meningitis sequelae disability weights for the minor 
conditions, it was decided to exclude these in the analysis. For vision problems, the “low 
vision” disability weight with a value of 0.223 from the corneal scar, onchocerciasis, and 
trachoma categories was used. As the majority of children in the clinical impairment 
category had hydrocephalus (a build-up of fluid inside the skull, leading to brain swelling), 
the GBD disability weight for long-term intracranial injury of 0.359 was used for clinical 
impairments. For multiple sequelae, a weight of 0.627 was assumed, which is the highest 
value in the GBD disability weight list, similar to dementia.34
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Table V
Sequelae case definitions and disability weights
Type
Minor sequelae Major sequelae
Case definition Case definition Disability weight
Cognitive deficit Learning difficulties or deficits 
with IQ >70 or speech/language 
impairment
Mental retardation with IQ <70 0.469
Seizures - Seizures of any type 0.099
Hearing loss Unilateral sensorineural hearing 
loss with audiometric hearing 
threshold level (averaged over 0.5, 
1, 2, 4 kHz) of >26 dBHL
Bilateral sensorineural hearing 
loss with audiometric hearing 
threshold level (averaged over 0.5, 
1, 2, 4 kHz in the better ear) of 
>26 dBHL
0.223
Motor deficit Isolated hypotonia, motor delay, 
ataxia, gait or coordination 
difficulties
Impairment, spasticity, or paresis 
of one or more limbs
0.388
Vision problems Unilateral visual disturbance, 
diplopia, nystagmus, or cranial 
nerve dysfunction
Presenting visual acuity in the best 
eye of less than 6/12 or 
corresponding visual field loss
0.223
Clinical impairments Any behavioral disorder attributed 
to the meningitis episode
Distinct pathologic entity with any 
impairment to activities of daily 
living
0.359
Multiple impairments Distinct pathologic entity with no 
impairment to activities of daily 
living: Mild cerebral dilatation
≥1 of above domains 0.627
Sources: Edmond (2010)33 for definitions and Mathers (2006) for disability weights.34
Table VI
Weighted average disability weights attributable to bacterial meningitis sequelae
Type of sequelae Disability weight Percent of cases Percent distribution
Weighted average 
disability weight
Hib
 Cognitive difficulties 0.469 1.0% 10% 0.049
 Seizure disorder 0.099 1.5% 16% 0.015
 Hearing loss 0.223 3.2% 33% 0.074
 Motor deficit 0.388 1.2% 13% 0.049
 Visual disturbance 0.223 0.1% 1% 0.002
 Clinical impairments 0.359 0.7% 7% 0.026
 Multiple impairments 0.627 1.9% 20% 0.124
 Total 9.6% 100.0% 0.340
Pneumococcal
 Cognitive difficulties 0.469 3.1% 13% 0.059
 Seizure disorder 0.099 2.5% 10% 0.010
 Hearing loss 0.223 6.7% 27% 0.061
 Motor deficit 0.388 3.3% 13% 0.052
 Visual disturbance 0.223 1.1% 4% 0.010
 Clinical impairments 0.359 3.4% 14% 0.050
 Multiple impairments 0.627 4.5% 18% 0.115
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Type of sequelae Disability weight Percent of cases Percent distribution
Weighted average 
disability weight
 Total 24.7% 100% 0.356
Meningococcal
 Cognitive difficulties 0.469 0.4% 6% 0.026
 Seizure disorder 0.099 0.5% 7% 0.007
 Hearing loss 0.223 2.1% 30% 0.066
 Motor deficit 0.388 0.8% 11% 0.044
 Visual disturbance 0.223 2.1% 30% 0.066
 Clinical impairments 0.359 0.2% 3% 0.050
 Multiple impairments 0.627 1.0% 14% 0.088
 Total 7.2% 100% 0.307
Source: Edmonds (2010).33
Weighted average disability weights for Hib, pneumococcal, and meningococcal meningitis 
sequelae were calculated from the disability weights in Table V, and the percentage 
breakdowns found in the literature review by Edmond et al (Table VI). The weighted 
disability weights were 0.340 for Hib, 0.356 for pneumococcal, and 0.307 for 
meningococcal meningitis sequelae. The 2 other types of meningitis serve as useful 
comparators to Hib meningitis sequelae.
Table VII
Overview of studies estimating the costs of pneumonia and meningitis treatment in children 
<5 years in low- and middle-income countries
First author Country Year
Types of diseases 
included Facilities included
No. of 
inpatient 
records 
reviewed*
Number of 
patient 
interviews 
for 
household 
costs*
Krishnan59 India 2001 Pneumonia, 
meningitis and 
diarrhea <5 y
2 primary, 4 secondary, 
and 2 tertiary hospitals
372 355
Guzman62 Columbia 2005 Pneumonia in 
children <2 y
3 tertiary hospitals 128 Not included
Hussain58 Pakistan 2006 Pneumonia and 
meningitis in 
children <5 y
2 primary, 2 secondary, 
and 1 tertiary hospital
589 Not included
Constenla61 Brazil, Chile 
and Uruguay
2007 Pneumonia and 
meningitis in 
children <5 y
33 hospitals and 10 
outpatient centers
753 Not included
Hussain56 Pakistan 2008 Pneumonia, 
severe pneumonia 
and very severe 
febrile disease in 
children <5 y
15 hospitals and 
clinics
NA 112
Chola57 Zambia 2009 Pneumonia and 
diarrhea in 
children <5 y
1 primary hospital 829 Not included
Ayieko56 Kenya 2009 Pneumonia, 
malaria, and 
3 primary, 3 secondary, 
and 1 tertiary hospital
307 205
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First author Country Year
Types of diseases 
included Facilities included
No. of 
inpatient 
records 
reviewed*
Number of 
patient 
interviews 
for 
household 
costs*
meningitis in 
children <5 y
Madsen55 India 2009 Severe 
pneumonia in 
children <3 y
1 secondary and 1 
tertiary hospital
56 56
Anh54 Vietnam 2010 Pneumonia, 
meningitis, and 
sepsis in children 
<5 y
1 tertiary hospital 980 Not included
Temple53 Fiji 2011 Outpatient 
pneumonia in 
children <5 y
2 tertiary hospital 
outpatient departments
400 400
Sinha60 South Africa 2012 Pneumonia in 
children <5 y
1 tertiary hospital 745 325
NA, nonapplicable.
*Count only for patients with pneumonia and meningitis. If other diseases were included in the study, these patients were 
excluded from the count.
Table VIII
Mean treatment costs of bacterial meningitis in tertiary hospitals (2010 US$)
Country Mean costs (SD) Reference
High-income:
 Australia 16 650 38
 Israel 13 043 36
 US 12 881 43
 France 11 570 41
 Sweden 10 490 39
 Australia 9886 37
 Slovenia 8366 42
 Republic of Korea 3509 44
Middle-income
 Chile 5855 61
 Russia 5616 46
 Uruguay 4203 61
 Columbia 1800 48
 South Africa 1702 45
 Brazil 1474 61
Low-income
 Pakistan 2758 58
 India 750 59
 Kenya 434 (365) 64
 Indonesia 292 50
 Vietnam 211 (172) 54
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Country Mean costs (SD) Reference
 Papua New Guinea 51 51
Hib Disease Treatment Costs
The costs of treating pneumonia and meningitis were estimated from regression analyses of 
country-specific data with GNI per capita as the independent variable. In a systematic 
literature review of economic evaluations of Hib vaccine, 15 studies reported on the costs of 
treating meningitis.35 These studies were from Australia, Colombia, France, Indonesia, 
Israel, Kenya, Papua New Guinea, Russia, Slovenia, South Africa, South Korea, and 
Sweden.36–52
Specific pneumonia and meningitis treatment cost studies from low- and middle-income 
countries were identified from authors’ files and PubMed. Eleven treatment cost studies, 
which were not part of Hib vaccine economic evaluations, were identified (Table VII). Six 
low-income countries (Fiji, India, Kenya, Pakistan, Vietnam, and Zambia53–59) and 5 
middle-income countries (Columbia, Chile, Brazil, South Africa, and Uruguay60–62) were 
represented. Sample sizes for estimating patient-specific costs ranged from 56 patients in 1 
of the 2 Indian studies to 980 patients in the study from Vietnam. Patient-specific resource 
utilization items, such as drugs, supplies, and diagnostic tests, were determined either by 
retrospectively reviewing patient records or by collecting data prospectively. Seven of the 
studies used microcosting methods of varying intensity for calculating the costs per hospital 
bed-day, which included annual costs of capital costs, staff, maintenance, electricity, 
consumables, etc. In 6 of the studies, caregivers were interviewed about their out-of-pocket 
costs, such as user fees and transport costs. A government health sector perspective was 
taken in the remaining 5 studies, with no household cost data collected.
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Figure 1. 
Correlation between GNI per capita and costs of treating meningitis (2010 US$).
Table IX
Mean inpatient pneumonia treatment costs per case (2010 US$)
Country Type of pneumonia Type of hospital Mean costs (SD or 95% CI) Reference
Vietnam Non-severe Tertiary 36 (33) 54
Vietnam Severe Tertiary 42 (47) 54
Uruguay All-cause Tertiary 80 61
Vietnam Very severe Tertiary 89 (85) 54
India All-cause Secondary 93 (72–114) 55
India All-cause Secondary 94 59
Kenya All-cause Secondary 95 64
Pakistan Non-severe Secondary 96 58
Brazil All-cause Tertiary 127 61
Zambia All-cause Primary 252 57
India All-cause Tertiary 162 (133–191) 55
Kenya All-cause Tertiary 270 (316) 64
Chile All-cause Tertiary 284 61
Pakistan Severe Secondary 317 58
India All-cause Tertiary 319 59
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Country Type of pneumonia Type of hospital Mean costs (SD or 95% CI) Reference
Brazil Pneumococcal Tertiary 628 61
South Africa Severe Primary 651 (607–694) 60
South Africa Severe Secondary 849 (793–906) 60
Columbia Bacterial Tertiary 1063 (914–1211) 62
South Africa Severe Tertiary 1160 (1083–1237) 60
Uruguay Pneumococcal Tertiary 2052 61
Chile Pneumococcal Tertiary 4502 61
Figure 2. 
Correlation between GNI per capita and costs of treating severe pneumonia (2010 US$).
Table X
Linear regression of the relationship between treatment costs and GNI per capita
n Constant Predictor F-test R2
Meningitis 21 774.27 0.2645 0.0001 0.8279
Pneumonia 9 54.49 0.1255 0.0037 0.7233
Estimates from all the 26 studies were converted to 2010 US$ values using local consumer 
price indices and average annual exchange rates.63 Mean treatment costs per case are 
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summarized in and Tables VIII and IV for meningitis and pneumonia, respectively. The 
costs per meningitis case ranged from US$51 in Papua New Guinea to US$16 650 in 
Australia, and the costs per case of severe pneumonia ranged from US$36 in Vietnam to US
$4502 in Chile. Although some of the variation between settings can be explained by 
methodological study differences, it is apparent that there is correlation between treatment 
costs and country income group.
Table XI
Statistical distributions and parameter values (minimum, maximum) used in the Monte Carlo 
simulation
Parameter
Statistical
distribution
GAVI-eligible
Africa GAVI-eligible Asia
Lower
middle-income
Upper
middle-income
Hib disease burden
 Incidence rates per 100 000 children aged <5 y
  Hib pneumonia Gamma 970 (243, 1698) 1,665 (238, 951) 852 (213, 1491) 589 (147, 1031)
  Hib meningitis Gamma 48 (14, 99) 31 (3, 71) 31 (4, 109) 22 (4, 96)
  Hib NPNM Gamma 3 (1, 6) 6 (1, 13) 4 (1, 13) 8 (1, 34)
 % CFRs in ages 1–59 mo (%):
  Hib pneumonia Beta 13 (8, 17) 10 (7, 12) 12 (8, 17) 6 (5, 14)
  Hib meningitis Beta 57 (37, 74) 44 (33, 55) 53 (38, 72) 29 (25, 60)
  Hib NPNM Beta 35 (14, 26) 18 (12, 25) 23 (15, 34) 10 (8, 27)
Hib meningitis survivors 
with major sequelae (%)
Beta 25 (19, 32) 22 (13, 32) 11% (8, 15) 9% (7, 12)
Hib vaccination coverage (%)
 Coverage of 1st dose Beta 41 (86, 99) 90 (81, 99) 95 (79, 99) 94 (74, 99)
 Coverage of 2nd dose Beta 80 (30, 99) 87 (78, 96) 92 (70, 99) 92 (60, 99)
 Coverage of 3rd dose Beta 76 (24, 99) 85 (77, 94) 91 (66, 99) 91 (46, 99)
Vaccine efficacy (%)
 1 dose Lognormal 63.4 (0.0, 88.7) 63.4 (0.0, 88.7) 63.4 (0.0, 88.7) 63.4 (0.0, 88.7)
 2 doses Lognormal 98.9 (0.0, 100.0) 98.9 (0.0, 100.0) 98.9 (0.0, 100.0) 98.9 (0.0, 100.0)
 3 doses Lognormal 0.0 (93.0, 97.0) 0.0 (93.0, 97.0) 0.0 (93.0, 97.0) 0.0 (93.0, 97.0)
Vaccine wastage (%) Beta 25 (20, 30) 25 (20, 30) 25 (20, 30) 5 (2, 7)
Health care utilization
 Number of outpatient visits per case:
  Hib pneumonia/NPNM Gamma 0.52 (0.31, 0.76) 0.54 (0.67, 0.81) 0.57 (0.34, 0.75) 0.86 (0.48, 0.90)
  Hib meningitis Gamma 1.55 (0.93, 2.27) 2.02 (1.62, 2.44) 1.71 (1.02, 2.25) 2.58 (1.44, 2.70)
 Number of inpatient admissions per case:
  Hib pneumonia/NPNM Gamma 0.05 (0.09, 0.13) 0.11 (0.09, 0.14) 0.10 (0.06, 0.13) 0.15 (0.08, 0.16)
  Hib meningitis Gamma 0.52 (0.31, 0.76) 0.67 (0.54, 0.81) 0.57 (0.34, 0.75) 0.86 (0.48, 0.90)
Treatment costs (2010 US$)
Household cost per 
outpatient clinic visit
Gamma 1.35 (1.01, 1.68) 1.52 (1.14, 1.90) 2.41 (1.81, 3.01) 2.77 (2.08, 3.46)
Government cost per 
outpatient clinic visit
Gamma 1.67 (1.25, 2.08) 1.48 (1.11, 1.85) 4.17 (3.13, 5.22) 8.90 (6.68, 11.13)
 Household costs per inpatient admission:
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Parameter
Statistical
distribution
GAVI-eligible
Africa GAVI-eligible Asia
Lower
middle-income
Upper
middle-income
  Hib pneumonia and NPNM:
   Secondary hospital Gamma 22 (15, 29) 23 (15, 31) 112 (58, 166) 614 (518, 710)
   Tertiary hospital Gamma 62 (41, 83) 79 (50, 107) 153 (79, 226) 839 (708, 970)
  Hib meningitis:
   Secondary hospital Gamma 150 (144, 156) 147 (140, 154) 614 (518, 710) 614 (518, 710)
   Tertiary hospital Gamma 426 (409, 444) 499 (475, 522) 564 (502, 625) 839 (708, 970)
 Government cost per inpatient admission:
  Hib pneumonia and NPNM:
   Secondary hospital Gamma 27 (18, 36) 23 (15, 31) 193 (101, 286) 1358 (1146, 1570)
   Tertiary hospital Gamma 77 (51, 103) 77 (49, 104) 264 (137, 391) 1566 (1856, 2146)
  Hib meningitis:
   Secondary hospital Gamma 185 (178, 193) 144 (137, 151) 714 (636, 791) 1358 (1146, 1570)
   Tertiary hospital Gamma 527 (505, 549) 488 (465, 511) 975 (869, 1081) 1856 (1566, 2146)
Linear regressions between mean treatment costs and GNI per capita were done using Stata 
v. 11.2. The regression lines are seen in Figures 1 and 2. In the pneumonia analysis, the 
result from Chile was excluded because this was a considerable outlier, and it was not 
possible to understand the underlying reasons for this in the original study.61 The 
correlations were highly significant for both diseases, with R2 of 83% for meningitis and 
72% for pneumonia (Table X).
The regression equations are as follows.
The studies from India, Kenya, and South Africa presented estimates for different levels of 
facilities, so that the costs in tertiary hospitals can be compared with costs at lower levels 
facilities. The ratios between costs at tertiary and secondary facilities were US$1.72 in India, 
US$2.84 in Kenya, and US$1.37 in South Africa. These rates were used for GAVI-eligible 
Asia, GAVI-eligible Africa, and the 2 middle-income groups, respectively.
Statistical Distributions of Parameters
Probabilistic uncertainty analysis was undertaken to simultaneously assess the uncertainty 
around all parameter values, generate 95% CIs around the ICERs and determine which 
parameters are most important for variation in the result.
Statistical distributions were fitted to all uncertain parameters that were not methodological 
or structural. Parameters with fixed values that were not considered uncertain, such as 
vaccine and syringe prices and the 2010 birth cohort, were not varied either. All distributions 
used are summarized in Table XI.
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Distributions were fitted to parameters according to recommendations by Briggs et al.65 The 
beta distribution was used for probability parameters with values between 0 and 1, such as 
case fatality rates and the risk of meningitis sequelae. The lognormal distribution is 
frequently used to fit relative risks and this was used for the vaccine efficacy parameters. 
Treatment costs are often highly skewed to the right and the gamma distribution was used to 
fit these data, including health care utilization parameters. The SD was assumed similar to 
the mean value of all cost estimates, reflecting the findings of most of the treatment cost 
studies reviewed. The gamma distribution was used to fit the disease incidence parameters 
because the mean values are likely to be conservative estimates due to the great difficulties 
in detecting Hib disease.
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Figure 1. 
Model framework. a, Clinical pneumonia incidence in children aged <5 years. b, Percent of 
clinical pneumonia caused by Hib. c, Hib NPNM incidence in children aged <5 years. d, Hib 
meningitis incidence in children aged <5 years. e, Pneumonia CFR without access to care. f, 
Pneumonia CFR with access to care. g, Hib NPNM CFR without access to care. h, Hib 
NPNM CFR with access to care. i, Hib meningitis CFR without access to care. j, Hib 
meningitis CFR with access to care. k, Proportion of Hib pneumonia cases seeking care. l, 
Proportion of cases of Hib NPNM seeking care. m, Proportion of cases of Hib meningitis 
seeking care. n, Proportion of Hib meningitis survivors with disability. o, Proportion with 
cognitive difficulties only. p, Proportion with seizure disorders only. q, Proportion with 
hearing loss only. r, Proportion with motor deficit only. s, Proportion with visual disturbance 
only. t, Proportion with multiple disabilities. u, Proportion with clinical impairments only.
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Figure 2. 
Histogram of Monte Carlo simulations for costs per discounted DALY averted.
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Figure 3. 
Contribution to variance of uncertain variables.
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Table II
Base case results of introducing Hib vaccine per 1 million birth cohort (societal perspective)
GAVI-eligible Africa GAVI-eligible Asia Lower middle-income Upper middle-income
Acute cases averted: 30 357 31 512 30 033 21 059
 Hib pneumonia 28 835 30 322 28 863 20 039
 Hib meningitis 1436 999 1049 748
 Hib NPNM 86 191 121 272
Meningitis sequelae 155 123 54 48
Premature deaths averted: 4589 3505 4048 1446
 Hib pneumonia 3749 3032 3464 1202
 Hib meningitis 818 439 556 217
 Hib NPNM 22 34 28 27
Percent of children aged <5 years 
mortality averted
3.59% 4.55% 10.94% 5.17%
Discounted DALYs averted 124 101 119 43
Outpatient visit costs averted (US$):
 Hib pneumonia 45 198 60 942 108 322 201 167
 Hib meningitis 6707 6051 11 815 22 529
 Hib NPNM 135 384 454 8192
Inpatient admission costs averted (US$):
 Hib pneumonia 150 751 189 215 913 521 2 280 831
 Hib meningitis 342 594 287 680 819 286 1 408 337
 Hib NPNM 450 1194 3832 495 220
Meningitis sequelae costs averted (US$) 3 040 950 2 262 331 1 480 874 2 243 964
Total costs averted (US$) 3 586 785 2 807 797 3 338 104 6 660 240
 Incremental vaccination costs (US$) 3 421 479 3 778 486 14 179 079 22 470 704
 Total incremental costs (US$) −165 308 970 688 10 840 973 15 810 462
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Table III
Incremental costs per discounted DALY averted (2010 US$)
GAVI-eligible Africa GAVI-eligible Asia Lower middle-income Upper middle-income
GNI per capita* 676 803 2888 7259
Government perspective
 Base case 25 35 110 453
 Mean (95% CI) from Monte Carlo 
simulation
35 (19, 57) 47 (26, 79) 138 (69, 234) 453 (202, 796)
 Median from Monte Carlo simulation 33 44 128 422
Societal perspective
 Base case Cost saving 10 91 369
 Mean (95% CI) from Monte Carlo 
simulation
−2 (−34, 22) 8 (−33, 48) 115 (37, 215) 368 (78, 733)
 Median from Monte Carlo simulation −3 9 108 348
*Source: World Bank.8
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